Capricor Therapeutics Inc (CAPR) Stock Analysis
Verdict: WATCH (do not buy)
Deramiocel Phase 3 DMD catalyst re-engagement is countered by negative earnings trends, high volatility, and cash burn.
Investment score: 42/100
Analysis as of
7-factor investment score
- Valuation: 35/100 (weight 20%)
- Financial Health: 70/100 (weight 15%)
- Technical Momentum: 40/100 (weight 15%)
- Earnings Quality: 30/100 (weight 15%)
- Insider Sentiment: 25/100 (weight 10%)
- Analyst Consensus: 55/100 (weight 10%)
- Risk-Adjusted Return: 40/100 (weight 15%)
Capricor Therapeutics Inc opportunities and risks
What speaks for CAPR
- Deramiocel (CAP-1002) Phase 3 DMD trial progression and FDA engagement
What speaks against CAPR
- Binary clinical and regulatory approval risk for lead drug deramiocel
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| CAPR | n/a | 0.0x | 0.5x | 0.0% | 0.0% | -27.0% |
| VSTM | n/a | 7.3x | n/a | 86.7% | -231.6% | -25.4% |
| ZURA | n/a | 0.0x | n/a | 0.0% | 0.0% | -15.7% |
| OVID | n/a | 317.2x | n/a | 100.0% | -2178.9% | -10.9% |
| IRD | n/a | 50.6x | n/a | 99.9% | -1091.8% | -8.2% |
| ARTV | n/a | 0.0x | n/a | 0.0% | 0.0% | -19.6% |
| Peer median | n/a | 7.3x | n/a | 86.7% | -231.6% | -15.7% |
Frequently asked questions about Capricor Therapeutics Inc (CAPR)
Is CAPR stock a good investment?
The TradeMates model rates Capricor Therapeutics Inc as WATCH (do not buy) with an investment score of 42/100. Deramiocel Phase 3 DMD catalyst re-engagement is countered by negative earnings trends, high volatility, and cash burn. This is algorithmic model output, not personal investment advice.
Is CAPR stock a buy?
The TradeMates model verdict for CAPR is WATCH (do not buy) with an investment score of 42/100. Treat this as a model signal to review, not a personal buy recommendation.